China conditionally approves AI-assisted antiviral Mprosevir

China’s National Medical Products Administration has granted conditional marketing approval to Mprosevir, also known as iscartrelvir hydrochloride. The oral antiviral is intended for adults with mild to moderate SARS-CoV-2 infection.

The drug was developed by Westlake University, Westlake Laboratory and Westlake Pharmaceuticals. Its developers describe it as China’s first innovative medicine to reach the market following an AI-assisted development process. That wording describes the use of a research tool; it does not mean an AI system independently created and validated the treatment.

Searching 49 billion compounds

The starting point was a DNA-encoded library, or DEL, containing about 49 billion compounds. This method allows a very large number of molecules to be screened simultaneously for their ability to bind to a biological target.

Initial tests produced more than one hundred candidates. Computational models then helped narrow the list and optimise molecular structures. The results still had to be checked through laboratory experiments, preclinical work and clinical trials.

Targeting a specific coronavirus enzyme

Mprosevir inhibits 3CLpro, a protease that SARS-CoV-2 needs to process proteins required for replication. Blocking the enzyme is therefore intended to slow the virus’s ability to reproduce in the body.

The developer says the medicine is administered without a separate boosting drug. That may reduce certain drug interactions, but its practical value must be assessed through the exact approval conditions, published clinical data and post-market monitoring.

Three and a half years does not mean full automation

According to the developers, about three and a half years passed from discovery of the candidate to completion of clinical trials. The relatively short timeline reflects the whole process: DEL screening, computational selection, medicinal chemistry, laboratory testing and a clinical programme.

AI’s contribution lies mainly in prioritising hypotheses and exploring large numbers of structures. Toxicity, dosage, efficacy and interactions remain experimental questions. A model can accelerate the choice of what deserves testing; it cannot replace the evidence required for approval.

What conditional approval means

The announced authorisation applies in China. It is not an approval in Belgium or the European Union and does not allow a direct comparison with treatments available here. Conditional approval also requires the holder to meet the regulator’s obligations and continue documenting safety and efficacy.

Detailed trial results, adverse effects, contraindications and performance against circulating variants will be essential to understand the medicine’s actual place in care. This is a report about a regulatory decision and a research method, not individual medical advice.

Sources

This summary draws on information published by China Daily and the developer’s product page. Photo: ThisIsEngineering, Pexels.